Breaking News Instant updates and real-time market news.

FB

Facebook

$169.25

-3.2 (-1.86%)

, DISCA

Discovery

$24.60

-2.2 (-8.21%)

16:21
07/31/17
07/31
16:21
07/31/17
16:21

On The Fly: Top stock stories for Monday

Stocks began the session in positive territory with the Dow leading the way and hitting a new all-time high in the process. By later in the morning, the Nasdaq crossed into negative territory and remained there for the rest of the session, weighed down by Facebook (FB) shares, which lost almost 2% following a rare downgrade of the stock to a sell rating. Oil prices bounced around but closed at session highs, with a rise of 1% pushing the commodity above $50 a barrel. ECONOMIC EVENTS: In the U.S., the Chicago PMI dropped 6.8 points to 58.9 in July, more than giving back its 6.3 point jump to 65.7 in June. The pending home sales index bounced 1.5% to 110.2 in June, which was better than expected. The Dallas Fed manufacturing index rose 1.8 points to 16.8 in July. In Asia, China's official government reading of its manufacturing PMI came in at 51.4, which was down from 51.7 in June, and the NBS services PMI slipped to 54.5 from 54.9 in June. Also, the Bank of Japan said it will keep its August bond purchase plans unchanged from July. In Europe, the flash estimate of the consumer price index for the euro area remained steady at 1.3% growth in July. Core inflation, excluding food and energy prices, rose to 1.2% in July. COMPANY NEWS: Discovery Communications (DISCA) announced this morning that the company agreed to acquire Scripps Networks Interactive (SNI) in a cash-and-stock transaction valued at $14.6B, or $90 per Scripps share. Discovery, which also reported quarterly results, slid over 8% following the deal announcement, while Scripps, which also warned about a Q2 revenue shortfall and cut its full year revenue outlook, advanced about 0.6% to $87.41 per share... Also in the media space, The Wall Street Journal reported over the weekend that Sprint (S) has proposed a merger with Charter Communications (CHTR). Charter met the report head on, announcing that while it understands "why a deal is attractive for SoftBank (SFTBF)...Charter has no interest in acquiring Sprint." According to CNBC, SoftBank's Masayoshi Son is still pursuing Charter and has lined up financing for a potential deal... Shares of Scana (SCG) rose 5% after its subsidiary South Carolina Electric & Gas Company announced it will cease construction of two new nuclear units at the V.C. Summer Nuclear Station in Jenkinsville, South Carolina and will file a petition with South Carolina PUC seeking approval of its abandonment plan... Time Warner (TWX) shares were in focus after Entertainment Weekly reported that HBO recently experienced a cyber incident, claiming that upcoming episodes of two series and at least one apparent script for a Game of Thrones episode were obtained. MAJOR MOVERS: Among the notable gainers was Dynavax (DVAX), which jumped about 71% after the company announced that an FDA advisory committee voted 12 to 1 that the safety data for Heplisav-B support licensure for immunization against hepatitis B infection in adults 18 years of age and older. Also higher was Bristol-Myers (BMY), which gained 3% after announcing a clinical collaboration agreement to evaluate the combination of the company's immunotherapy Opdivo and Clovis' (CLVS) "PARP inhibitor" Rubraca in phase 3 cancer trials. Clovis shares fell 13.5% following the partnership announcement. Also lower was Facebook, which slid 1.9% after Pivotal Research analyst Brian Wieser downgraded the stock to Sell, as he thinks the market is looking at upside potential without appropriately considering risks to growth. Additionally, Tesla (TSLA) fell 3.5% after Business Insider reported that workers at the car maker's Fremont facility, who have been agitating for a union, have sent a list of demands to the company's board. INDEXES: The Dow rose 60.81, or 0.28%, to 21,891.12, the Nasdaq lost 26.55, or 0.42%, to 6,348.12, and the S&P 500 dipped 1.80, or 0.07%, to 2,470.30.

FB

Facebook

$169.25

-3.2 (-1.86%)

DISCA

Discovery

$24.60

-2.2 (-8.21%)

SNI

Scripps Networks

$87.41

0.5 (0.58%)

S

Sprint

$7.98

-0.24 (-2.92%)

CHTR

Charter

$391.91

21.65 (5.85%)

SCG

Scana

$64.37

3.08 (5.03%)

TWX

Time Warner

$102.42

-0.31 (-0.30%)

DVAX

Dynavax

$15.85

6.6 (71.35%)

BMY

Bristol-Myers

$56.90

1.63 (2.95%)

CLVS

Clovis

$84.81

-13.21 (-13.48%)

TSLA

Tesla

$323.47

-11.6 (-3.46%)

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 03

    Aug

  • 08

    Aug

  • 09

    Aug

  • 10

    Aug

  • 14

    Aug

  • 16

    Aug

  • 18

    Aug

  • 11

    Sep

  • 13

    Sep

  • 24

    Sep

  • 02

    Oct

  • 09

    Nov

  • 05

    Mar

FB Facebook
$169.25

-3.2 (-1.86%)

07/27/17
NEED
07/27/17
NO CHANGE
Target $185
NEED
Buy
Facebook 'strong over-delivery' a negative for Snap, says Needham
Needham analyst Laura Martin believes Facebook's (FB) "strong over-delivery" of Q2 earnings is negative for Snap (SNAP) because Instagram Stories hit 250M DAU's in Q2, well above Snap's 166M DAU's in Q1. The analyst reiterates a Buy rating and $185 price target on Facebook's shares.
07/31/17
PIVT
07/31/17
DOWNGRADE
Target $140
PIVT
Sell
Facebook downgraded to Sell from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Facebook (FB) to Sell with an unchanged price target of $140. The social network closed Friday up $2.01 to $172.45. The shares are not factoring in risks to the company's growth following their "remarkable run" this year, Wieser tells investors in a research note. The recent European Commission ruling on Google (GOOG, GOOGL) Shopping and the agency's approach to dominant companies in general poses a greater risk as Facebook becomes larger, the analyst contends.
07/27/17
JMPS
07/27/17
NO CHANGE
JMPS
Facebook price target raised to $195 from $170 at JMP Securities
JMP Securities analyst Ronald Josey believes that Facebook's Q2 results shows that higher ad prices can offset declines in ad loads. The analyst says that the company's "core fundamentals" are strong, and he keeps an Outperform rating on the shares.
07/31/17
07/31/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Sell from Hold at Pivotal Research with analyst Brian Wieser saying the shares are not factoring in risks to the company's growth following their "remarkable run" this year. 2. Ulta Beauty (ULTA) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh saying softer commentary from L'Oreal on its earnings call, increasing promotional activity from the department store channel, and more difficult year-over-year comparisons "could now signal a potentially more challenging beauty backdrop going forward." 3. Hertz (HTZ) downgraded to Underweight from Equal Weight at Barclays with analyst Brian Johnson saying fundamentals may have bottomed, but the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since June 21. 4. Citi (C) downgraded to Market Perform from Outperform at BMO Capital with analyst James Fotheringham citing valuation and lack of catalysts. 5. Visteon (VC) downgraded to Neutral from Buy at UBS with analyst Colin Langan saying the risk/reward is more balanced with the shares up 60% over the last year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DISCA Discovery
$24.60

-2.2 (-8.21%)

07/25/17
NEED
07/25/17
NO CHANGE
NEED
Hold
Needham likes Scripps Networks best as Discovery merger partner
Needham analyst Laura Martin believes Discovery (DISCA) will decide to protect its U.S. asset value rather than exit, and likes Scripps Networks (SNI) best as a merger partner for the company. The analyst reiterates a Hold rating on Discovery's shares.
07/31/17
LOOP
07/31/17
NO CHANGE
LOOP
Hold
Discovery deal accretion not enough to get 'overly excited,' says Loop Capital
Loop Capital analyst David Miller said that Discovery's (DISCA) agreement to acquire Scripps Networks (SNI) is accretive, but not enough to get him "overly excited." Miller, who views the well-telegraphed deal as more "playing defense" than anything else, keeps a Hold rating on Discovery shares.
07/26/17
WELS
07/26/17
NO CHANGE
WELS
Scripps Networks could be acquired for $91-$95 per share, says Wells Fargo
After the Wall Street Journal reported that Discovery (DISCA) and Viacom (VIAB) are interested in buying Scripps' (SNI) assets, Wells Fargo estimates that Scripps could be acquired for $91-$95 per share. The firm believes that the acquirer or acquirers could realize a total of about $175M of non-programming expense synergies. It keeps a Market Perform rating on Scripps.
07/31/17
MOFT
07/31/17
UPGRADE
MOFT
Neutral
Scripps Networks upgraded to Neutral from Sell at MoffettNathanson
MoffettNathanson analyst Michael Nathanson upgraded Scripps Networks (SNI) to Neutral and raised his price target for the shares to $87 from $61 after the company agreed to be acquired by Discovery (DISCA).
SNI Scripps Networks
$87.41

0.5 (0.58%)

S Sprint
$7.98

-0.24 (-2.92%)

07/31/17
JPMS
07/31/17
NO CHANGE
Target $450
JPMS
Overweight
Charter offer would likely have to be at least $500 per share, says JPMorgan
JPMorgan analyst Philip Cusick believes SoftBank (SFTBY) is one of the few companies that could offer a big enough price to take control of Charter Communications (CHTR). While a deal is not very likely, Softbank Chairman Masayoshi Son "is never to be counted out as a buyer," Cusick tells investors in a research note. He believes a Charter acquisition offer would likely have to be in the $500 per share or higher range. Charter shares in premarket trading are up $31.74 to $402 after the Wall Street Journal reported Friday night that SoftBank has interest in merging the company with Sprint. Cusick estimates annual synergies between Sprint (S) and Charter could be around $2B, with minimal cost to integrate versus a Sprint and T-Mobile (TMUS) merger "which would have more eventual cost savings but cost much more to integrate." A Sprint and Charter deal would not have a difficult regulatory review, the analyst believes. Cusick adds that if Charter looked like it was going to sell to Softbank, Comcast (CMCSA) would have to decide if it ever did want to buy Charter and "move more quickly with an even bigger premium."
05/30/17
MOFT
05/30/17
NO CHANGE
MOFT
U.S. telecom sector upgraded to Neutral from Sell at MoffettNathanson
MoffettNathanson analyst Craig Moffett upgraded the U.S. telecom sector to Neutral from Sell. As reasons for the upgrade, the analyst cited valuation, lack of near-term negative catalysts, interest rate easing, and a potential merger between Sprint (S) and T-Mobile (TMUS). Other stocks in the sector include Verizon (VZ) and AT&T (T). The firm today upgraded AT&T to Neutral from Sell.
05/30/17
BTIG
05/30/17
NO CHANGE
BTIG
Verizon shares could rise to $51 but outlook still mixed, says BTIG
BTIg analyst Walter Piecyk believes that Verizon's (VZ) stock can rise to $51. He notes that the company's wireless "margins and churn are still near record levels," while Sprint's (S) CEO expects prices for unlimited data plans to rise. Additionally, the analyst believes that the chances of Verizon making "a large dilutive acquisition" have decreased, while Verizon would benefit from a merger of Sprint and T-Mobile (TMUS). However, the analyst lowered his estimates for Verizon ,and he thinks that the company's dividend could be at risk over the longer term. Moreover, he warns that the stock could come under pressure if the T-Mobile/Sprint merger falls through, while a new , "well-funded" competitor could enter the wireless space. He keeps a Neutral rating on Verizon.
06/27/17
JEFF
06/27/17
NO CHANGE
JEFF
Jefferies sees Sprint takeover by Comcast, Charter as less likely
Jefferies analyst Mike McCormack says this morning's Wall Street Journal report exclusive talks between Sprint (S) and Comcast (CMCSA)/Charter (CHTR) is not surprising. He believes the cable operators are looking for better MVNO terms and that an outright acquisition or equity stake is less likely. The report provides an indication of just how far apart Sprint and T-Mobile (TMUS) may be in any discussions, McCormack tells investors in a research note. The exclusive talks may also push T-Mobile closer to DISH (DISH), the analyst adds.
CHTR Charter
$391.91

21.65 (5.85%)

06/08/17
MOFT
06/08/17
NO CHANGE
MOFT
Charter spectrum values likely falling, says MoffettNathanson
MoffettNathanson said spectrum values are likely falling rather than rising, and investors are likely overestimating what buyers are willing to pay, a negative for current spectrum owners. The firm's analyst said Charter is likely a long-term acquirer, but near-term acquisitions are unlikely given the integrations of Time Warner Cable and Bright House.
06/01/17
OPCO
06/01/17
INITIATION
OPCO
Perform
Charter initiated with a Perform at Oppenheimer
Oppenheimer analyst Timothy Horan initiated Charter with a Perform rating saying free cash flow growth is reflected in valuation.
SCG Scana
$64.37

3.08 (5.03%)

07/28/17
GUGG
07/28/17
DOWNGRADE
GUGG
Sell
Scana downgraded to Sell from Buy at Guggenheim
03/03/17
UBSW
03/03/17
UPGRADE
Target $77
UBSW
Buy
SCANA upgraded to Buy from Neutral at UBS
UBS analyst Julien Dumoulin-Smith upgraded SCANA to Buy and raised its price target to $77 from $75 saying shares have underperform on Toshiba concerns. The analyst said Toshiba concerns have largely reached an apex for now and believes Q1 updates indicate the latest delay will actually be quite modest. He believes the most recent actions by Toshiba to sell off other businesses rather than addressing the Westinghouse business head-on following the $6B writedown in December gives him confidence on its implicit commitment.
07/20/17
GSCO
07/20/17
UPGRADE
Target $66
GSCO
Neutral
Scana upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Michael Lapides upgraded Scana to Neutral saying construction and cost concerns are now priced into the shares. The analyst raised his price target for the stock to $66 from $64.
07/28/17
GABE
07/28/17
DOWNGRADE
GABE
Hold
Scana downgraded to Hold from Buy at Gabelli
Gabelli downgraded Scana to Hold to reflect increased concern the company abandons the construction of VC Summer Nuclear Power Plant units 2 & 3.
TWX Time Warner
$102.42

-0.31 (-0.30%)

07/13/17
BOFA
07/13/17
DOWNGRADE
Target $39
BOFA
Neutral
AT&T downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst David Barden downgraded AT&T (T) to Neutral from Buy and cut its price target to $39 from $46 on reduced visibility into catalysts such as corporate tax reform and potential headwinds from the Time Warner (TWX) merger. Barden expects the associated overhang of $40B in new equity issuance and the tightening of the deal spread will increasingly pressure AT&T's stock. Additionally, the analyst trimmed Q2 estimates due to a seasonally difficult quarter saying video, voice, and broadband metrics are expected to be challenging and AT&T is losing share in each category.
04/20/17
04/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) downgraded to Peer Perform from Outperform at Wolfe Research with analyst Scott Mushkin saying shares are approaching his price target and he expects increasing competition through year-end. 2. Time Warner (TWX) downgraded to Hold from Buy at Pivotal Research with analyst Brian Wieser saying shares are trading near the value of AT&T's (T) offering price. 3. Molson Coors (TAP) downgraded to Market Perform from Outperform at Cowen with analyst Vivien Azer citing expectations for persistent beer volume headwinds. The analyst believes alcohol consumption could be pressured for at least the next decade, partly due to increased cannabis use, and a contraction in the alcohol cycle. Azer said Molson is uniquely exposed to the increasingly vibrant and growing cannabis markets and notes there is an inverse relationship between cannabis use and alcohol consumption over time. 4. eBay (EBAY) downgraded to Neutral from Buy at Monness Crespi with analyst James Cakmak saying he sees insufficient upside to estimates to justify the lofty valuation. The analyst said the path to double-digit growth may be pushed out 2019 and limited potential to outperform topline expectations in 2017. Further, the analyst sees margin pressures from product mix towards StubHub and rising development spend for the backend, and limited opportunities for multiple expansion. 5. Ruth's Hospitality (RUTH) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/17
OPCO
04/24/17
NO CHANGE
OPCO
Sprint, DISH the only assets for sale, says Oppenheimer
Oppenheimer analyst Timothy Horan noted that wireless companies will be allowed to discuss M&A, and says he sees Sprint (S) and possibly DISH (DISH) as the only assets for sale. The analyst believes the most likely outcome is for consolidation around the four major wireless providers, something along the lines of Charter (CHTR)/Sprint, T-Mobile (TMUS)/Comcast (CMCSA; CMCSK), Verizon (VZ)/DISH, with AT&T's (T) position "fairly solidified" with DirectTV/Time Warner (TWX). Further, Horan suspects Sprint will be sold first, most likely to Charter, although T-Mobile is a possibility and could be the controlling company/management and likely paying a premium for Sprint.
05/03/17
05/03/17
DOWNGRADE

Hold
Wunderlich downgrades Charter on valuation, sees some level of M&A priced in
As previously reported, Wunderlich analyst Matthew Harrigan downgraded Charter (CHTR) to Hold from Buy, citing valuation. He thinks that the current stock price imbeds some expectation for merger activity, apart from an eventual collapse of the Liberty Broadband (LBRDA) and Liberty Ventures (LVNTA) ownership structure, he tells investors. While a theoretical merger with Verizon (VZ) is "at least as strategically compelling" as AT&T's (T) deal for Time Warner (TWX), Harrigan thinks that price and regulatory hurdles could be difficult to overcome. He cut his price target on Charter to $350 from $360.
DVAX Dynavax
$15.85

6.6 (71.35%)

07/31/17
WBLR
07/31/17
NO CHANGE
WBLR
Outperform
Dynavax fair value estimate raised to $30 from $17 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate for Dynavax shares to $30 after an FDA panel voted 12-1 that the safety to date supports Heplisav approval for vaccination against hepatitis B infection in adults over 18 years old. The analyst believes the vote will lead to approval of Heplisav on its FDA action date of August 10. Dynavax's oncology candidates, if successful, could generate higher value than Heplisav for the shares, Xu tells investors in a research note. She keeps an Outperform rating on the name.
07/31/17
RBCM
07/31/17
UPGRADE
RBCM
Outperform
Dynavax upgraded on positive FDA panel at RBC Capital
As noted earlier, RBC Capital upgraded Dynavax to Outperform from Sector Perform. Analyst Matthew Eckler says that a positive report from an FDA panel on the company's HEPLISAV-B vaccine significantly lowers the vaccine's risk and could cause investors to become interested in the stock again. The analyst is upbeat on the vaccine's outlook and raised his price target on the shares to $26 from $7.
07/31/17
RBCM
07/31/17
UPGRADE
RBCM
Outperform
Dynavax upgraded to Outperform from Sector Perform at RBC Capital
07/31/17
JPMS
07/31/17
UPGRADE
Target $27
JPMS
Overweight
Dynavax upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Dynavax to Overweight and raised his price target for the shares to $27 from $6. Following last week's FDA panel, the analyst now believes that hepatitis B vaccine Heplisav has a high probability of approval by the August 10 action date. He expects "rapid uptake" and sees $450M-plus in peak sales in the U.S. alone. Further, Rama believes SD-101 has compelling early-stage data in treatment-naive melanoma. The analyst views the asset as underappreciated.
BMY Bristol-Myers
$56.90

1.63 (2.95%)

07/31/17
LEER
07/31/17
NO CHANGE
LEER
Outperform
Clovis weakness unwarranted after Bristol-Myers pact, says Leerink
Leerink analyst Michael Schmidt thinks today's weakness in Clovis (CLVS) is unwarranted following the company's clinical collaboration agreement with Bristol-Myers (BMY) and presents a buying opportunity. This deal does not preclude a future acquisition of the company, but it does increase the competitiveness and value of Rubraca, argues Schmidt, who reiterates his Outperform rating on Clovis shares.
07/27/17
LEER
07/27/17
NO CHANGE
LEER
Outperform
AstraZeneca trial failure negative for Bristol-Myers, says Leerink
Leerink analyst Seamus Fernandez notes that AstraZeneca (AZN) announced that the MYSTIC trial failed to show a progression-free survival benefit for Imfinzi + tremelimumab compared to chemotherapy in first-line non-small cell lung cancer patients with PDL1 expression greater than 25%. The read through is an obvious negative readthrough for Bristol-Myers' (BMY) combo of Opdivo + Yervoy in the ongoing CheckMate-227 trial, the analyst says. He points out that while there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes. Fernandez reiterates an Outperform rating on Bristol-Myers' shares.
07/31/17
JANY
07/31/17
NO CHANGE
Target $107
JANY
Buy
Clovis partnership undercuts takeover thesis, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay says Clovis Oncology's (CLVS) clinical partnership with Bristol-Myer Squibb (BMY) undercuts his takeout thesis. The recent agreements across the PARP drugs implies no near-term takeovers, Chattopadhyay tells investors in a research note. He believes this will "likely to be disappointing to many." The analyst has a Buy rating on Clovis with a $107 price target. The shares in early trading are down $8.04, or 8% to $89.97.
07/28/17
LEER
07/28/17
NO CHANGE
Target $61
LEER
Outperform
Bristol-Myers price target lowered to $61 after Astra trial setback at Leerink
Leerink analyst Seamus Fernandez said Bristol-Myers (BMY) reported "solid" Q2 results, including encouraging growth for its key franchises, but he sees increased uncertainty following the failure of AstraZeneca's (AZN) MYSTIC trial, which has potential read through to Bristol's CheckMate-227 trial of its I/O combo of Opdivo + Yervoy. Fernandez lowered his price target on Bristol shares to $61 from $66, but "fully acknowledges" the range of differences in the trial designs. He keeps an Outperform rating on Bristol-Myers, citing prospects for monotherapy Opdivo approval in the second-line setting and success in first-line liver cancer.
CLVS Clovis
$84.81

-13.21 (-13.48%)

07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
07/31/17
JPMS
07/31/17
NO CHANGE
JPMS
Clovis takeover thesis not off the table, says JPMorgan
JPMorgan said the Clovis (CLVS) and Bristol-Myers (BMY) collaboration does not impact the takeover thesis of Clovis. Analyst Cory Kasimov said the the no-strings-attached clinical collaboration has no financial terms aside from provision of study drug and sharing of trial costs in some instances and Bristol does not have first rights of refusal if an interested party did approach Clovis.
TSLA Tesla
$323.47

-11.6 (-3.46%)

07/20/17
07/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Citi. 2. Johnson & Johnson (JNJ) reinstated with an Outperform at Credit Suisse. 3. Tile Shop (TTS) initiated with a Hold at Loop Capital. 4. Spring Bank Pharmaceuticals (SBPH) initiated with an Overweight at Cantor. 5. Discovery (DISCA) and Scripps Networks (SNI) were initiated with a Market Perform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/17
UBSW
07/26/17
NO CHANGE
Target $185
UBSW
Sell
Tesla has risks around quality, servicing, charging needs, says UBS
UBS analyst Colin Langan said the Model 3 media event for Tesla on July 28 is key to maintaining its hype and a positive media reaction is important. The analyst believes the stock's recent run is due to the company maintaining its production schedule and its sales assumptions, which put them in line with BMW's. Langan remains cautious on the company's earnings and cash burn and reiterated his Sell rating and $185 price target on Tesla shares.
07/26/17
BARD
07/26/17
NO CHANGE
Target $368
BARD
Outperform
Tesla weakness after Q2 report would be buying opportunity, says Baird
Baird analyst Ben Kallo previewed Tesla's Q2 results, noting investors will be focusing on demand commentary. The analyst believes the shares could move higher heading into the company's Model 3 event and fall on its Q2 results next Tuesday. Kallo, who would use any post-earnings weakness as a buying opportunity, reiterated his Outperform rating and $368 price target on Tesla shares.
07/20/17
SBSH
07/20/17
INITIATION
Target $357
SBSH
Neutral
Tesla initiated with a Neutral at Citi
Citi analyst Itay Michael started Tesla shares with a Neutral rating and $357 price target. The shares closed yesterday down $2.98 to $325.26. The analyst is positive on Tesla's position as the "Car of the Future leader," and thinks upside from current levels could "still be significant," but he prefers to wait for a better entry point. Michael would like to see a stronger balance sheet or "convincing signs of a smooth Model 3 ramp with limited Model S cannibalization" before getting more positive on the shares. Both the bull and bear cases on Tesla shares "carry some merit," the analyst tells investors in a research note.

TODAY'S FREE FLY STORIES

KKR

KKR

$18.56

-0.085 (-0.46%)

13:31
08/23/17
08/23
13:31
08/23/17
13:31
Periodicals
KKR considers sale of French gas-fired power plants, Reuters reports »

KKR is mulling the sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSEM

Tower Semiconductor

$27.12

0.7 (2.65%)

13:30
08/23/17
08/23
13:30
08/23/17
13:30
Options
Bullish flow in Tower Semi as shares set 52-week highs »

Bullish flow in Tower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

13:30
08/23/17
08/23
13:30
08/23/17
13:30
General news
NY Fed accepted $169.8 B in daily reverse repos »

NY Fed accepted $169.8 B…

OMER

Omeros

$21.29

0.49 (2.36%)

13:22
08/23/17
08/23
13:22
08/23/17
13:22
Periodicals
Omeros 'still won't answer basic questions,' STAT's Feuerstein says »

Omeros' press…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUB

People's Utah Bancorp

$27.00

0.05 (0.19%)

13:20
08/23/17
08/23
13:20
08/23/17
13:20
Hot Stocks
People's Utah Bancorp CEO sells 12,170 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$20.44

0.54 (2.71%)

13:20
08/23/17
08/23
13:20
08/23/17
13:20
Options
Second day of interest in CenturyLink September puts »

Second day of interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETS

PetMed Express

$39.41

-2.32 (-5.56%)

13:17
08/23/17
08/23
13:17
08/23/17
13:17
Hot Stocks
PetMed Express tells Bloomberg Aurelius report 'false and defamatory' »

In response to an earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

$NSD

NASDAQ Market Internals

13:17
08/23/17
08/23
13:17
08/23/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRE

Sempra Energy

$118.03

-0.25 (-0.21%)

13:16
08/23/17
08/23
13:16
08/23/17
13:16
Conference/Events
Sempra Energy to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 14

    Sep

$NYE

NYSE Market Internals

13:16
08/23/17
08/23
13:16
08/23/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
08/23/17
08/23
13:15
08/23/17
13:15
General news
Jackson Hole outlook: »

Jackson Hole outlook: the…

CAVM

Cavium

$60.98

0.84 (1.40%)

13:15
08/23/17
08/23
13:15
08/23/17
13:15
Conference/Events
Cavium has a conference call hosted by William Blair »

William Blair Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 06

    Sep

PETS

PetMed Express

$39.41

-2.32 (-5.56%)

13:12
08/23/17
08/23
13:12
08/23/17
13:12
Recommendations
PetMed Express analyst commentary  »

PetMed Express recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

SIX

Six Flags

$51.97

-1.25 (-2.35%)

, DIS

Disney

$102.04

-0.73 (-0.71%)

13:06
08/23/17
08/23
13:06
08/23/17
13:06
Hot Stocks
Six Flags Magic Mountain to launch 365-day operation on January 1 »

Six Flags Entertainment…

SIX

Six Flags

$51.97

-1.25 (-2.35%)

DIS

Disney

$102.04

-0.73 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

S

Sprint

$8.29

0.065 (0.79%)

, SSNLF

Samsung

$2,030.00

-70 (-3.33%)

13:05
08/23/17
08/23
13:05
08/23/17
13:05
Hot Stocks
Samsung Galaxy Note8 coming to Sprint for $20 a month »

Sprint (S) announced the…

S

Sprint

$8.29

0.065 (0.79%)

SSNLF

Samsung

$2,030.00

-70 (-3.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

WSM

Williams-Sonoma

$43.04

0.19 (0.44%)

13:05
08/23/17
08/23
13:05
08/23/17
13:05
Options
Williams Sonoma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

MSI

Motorola Solutions

$86.67

0.26 (0.30%)

, ZURVY

Zurich Insurance

$30.34

-0.04 (-0.13%)

13:04
08/23/17
08/23
13:04
08/23/17
13:04
Hot Stocks
Motorola Solutions names Troy Mattern as head of product cybersecurity »

Motorola Solutions (MSI)…

MSI

Motorola Solutions

$86.67

0.26 (0.30%)

ZURVY

Zurich Insurance

$30.34

-0.04 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

HPQ

HP Inc.

$18.91

-0.115 (-0.60%)

, HPE

HP Enterprise

$17.69

0.02 (0.11%)

12:56
08/23/17
08/23
12:56
08/23/17
12:56
Earnings
On The Fly: What to watch in HP Inc.'s earnings report »

HP Inc. (HPQ) is…

HPQ

HP Inc.

$18.91

-0.115 (-0.60%)

HPE

HP Enterprise

$17.69

0.02 (0.11%)

LNVGY

Lenovo

$11.13

-0.07 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 05

    Sep

  • 06

    Sep

BABA

Alibaba

$173.90

-0.562 (-0.32%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on Alibaba »

Alibaba mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ON

ON Semiconductor

$16.04

0.29 (1.84%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on ON Semiconductor »

ON Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

KRO

Kronos Worldwide

$19.25

-0.25 (-1.28%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on Kronos Worldwide »

Kronos Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
08/23/17
08/23
12:55
08/23/17
12:55
General news
U.S. VIX equity volatility is up 4% near 11.82 »

U.S. VIX equity…

HCCI

Heritage-Crystal Clean

$18.15

-0.05 (-0.27%)

12:54
08/23/17
08/23
12:54
08/23/17
12:54
Periodicals
Breaking Periodicals news story on Heritage-Crystal Clean »

Heritage-Crystal Clean…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 08

    Sep

  • 09

    Sep

12:50
08/23/17
08/23
12:50
08/23/17
12:50
General news
Breaking General news story  »

Dallas Federal Reserve…

CVM

CEL-SCI

$1.95

-0.341 (-14.89%)

12:47
08/23/17
08/23
12:47
08/23/17
12:47
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI »

Sabby Management reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.